MAPT and Alzheimer disease: Few studies investigated early phases tau-PET as a potential biomarker of neuronal injury in tauopathies [20] and specifically in AD [14], providing evidence of good correspondence with 18F-FDG-PET images and also with early phase of amyloid-PET [21] at the group level.